一个国际网络（妇科癌症国际协作组）开展的临床研究对全球妇科癌症临床试验能力的影响。
The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials.
作者信息
Stuart Gavin C E, Kitchener Henry C, Vermorken Jan B, Quinn Michael J, Small William, Pujade-Lauraine Eric, Chou Hansen, Wong Michelle, Bacon Monica
机构信息
*Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada; †Institute of Cancer Sciences, University of Manchester, Manchester, England; ‡European Organization for Research and Treatment for Cancer, Belgium; §Department of Obstetrics and Gynecology, University of Melbourne, Melbourne, Australia; ∥Department of Radiation Oncology, Loyola University Chicago, Chicago, IL; ¶AP-HP, Hôpital Hôtel-Dieu, Université Paris Descartes, Paris, France; #Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; and **Gynecologic Cancer InterGroup, Kingston, Ontario, Canada.
出版信息
Int J Gynecol Cancer. 2017 May;27(4):813-818. doi: 10.1097/IGC.0000000000000934.
OBJECTIVE
The objective of this study was to demonstrate that the construction of the Gynecologic Cancer InterGroup (GCIG) has increased collaboration and accrual to high-quality phase 3 trials at a global level.
MATERIALS AND METHODS
The GCIG is a collaboration of 29 international cooperative clinical trial groups committed to conduct of high-quality phase 3 trials among women with gynecologic cancer. A complete bibliography of the reported phase 3 trials has been developed and is available on the GCIG Web site http://www.gciggroup.com. A "GCIG trial" is a trial in which any 2 or more GCIG member groups are formally involved. We reviewed the output of the GCIG from 1997 to 2015 with respect to member participation and quality of publication (impact factor and citation index). The publications are considered in 3 cohorts, 1997 to 2002, 2003 to 2008, and 2009 to 2014, for the purposes of comparison and progress. A social network map has been developed for these publications to identify how the GCIG has increased capacity for clinical trials globally.
RESULTS
Using a global map, the number of member groups in the GCIG has increased in each of the 3 periods. The total annual number of publications and citations within the 1997 to 2015 period has increased significantly. The average number of citations per publication is demonstrated in each of the 3 periods. The steady increase in the number of citations is used as a proxy for the impact of the publications. The impact factor of the journal and the number of citations are reported for the 10 most highly cited publications. Finally, using a social networking methodology, networking has visibly and numerically increased in each of the 3 periods.
CONCLUSIONS
Evidence supports that the construction of the GCIG has increased collaboration and accrual to high-quality phase 3 trials at a global level among women with gynecologic cancer.
目的
本研究的目的是证明妇科癌症国际协作组（GCIG）的组建在全球范围内增加了高质量3期试验的协作与入组。
材料与方法
GCIG是由29个国际合作临床试验组组成的协作组织，致力于在妇科癌症女性患者中开展高质量3期试验。已编制了已报告的3期试验的完整参考文献目录，并可在GCIG网站http://www.gciggroup.com上获取。“GCIG试验”是指有任何2个或更多GCIG成员组正式参与的试验。我们回顾了1997年至2015年GCIG在成员参与和发表质量（影响因子和被引指数）方面的成果。为了进行比较和评估进展情况，将这些出版物分为1997年至2002年、2003年至2008年以及2009年至2014年三个队列进行考量。已为这些出版物绘制了社交网络图，以确定GCIG如何在全球范围内提高临床试验能力。
结果
通过全球地图显示，在这三个时期中的每个时期，GCIG的成员组数量都有所增加。1997年至2015年期间的年度出版物总数和被引次数均显著增加。展示了三个时期中每个时期每篇出版物的平均被引次数。被引次数的稳步增加被用作出版物影响力的一个指标。报告了被引次数最高的10篇出版物的期刊影响因子和被引次数。最后，使用社交网络方法，在这三个时期中的每个时期，网络联系在可见性和数量上都有所增加。
结论
有证据支持GCIG的组建在全球范围内增加了妇科癌症女性患者高质量3期试验的协作与入组。
Zotero 插件